By documenting the promising benefits of SGLT2 inhibition including tighter BS control, acceptable HbA1c range, lower required doses of insulin, and no severe hypoglycemia over the age of 5 along with normal growth and development, we hope to pave the path to greenlighting its use in children older than 5 with T1DM (Table 1, Figure 1). The gene discussed is SLC5A2; the disease is Hypoglycemia.